Latanoprost Accord-Uk (Latanoprost)

Latanoprost binds to FP prostanoid receptors in the eye’s ciliary body, triggering biochemical changes that increase the outflow of aqueous humor through the uveoscleral pathway. This enhanced drainage reduces intra‑ocular pressure, the primary risk factor in glaucoma.

The specific dosing regimen for Latanoprost Accord-Uk is determined by the prescribing clinician based on the patient’s condition, response, and ocular health. Typically, a single drop is instilled in the affected eye(s) once daily, but exact instructions must come from a qualified eye‑care professional.

Safety data for Latanoprost in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by the treating physician.

To request Latanoprost Accord-Uk, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Latanoprost belongs to the prostaglandin analog class, which generally offers once‑daily dosing and strong intra‑ocular pressure reduction. Compared with beta‑blocker or carbonic anhydrase inhibitor drops, prostaglandin analogs often have a more favorable dosing convenience and comparable efficacy, though individual response and side‑effect profiles may vary.

Latanoprost Accord-Uk should be stored at room temperature, below 25 °C, in its original packaging. Protect the bottle from direct light and moisture, and keep it out of reach of children. Do not freeze the product.

Latanoprost Accord-Uk is administered as an ocular solution. The patient places a single drop into the affected eye(s) as directed by the eye‑care professional, typically once daily in the evening. Hands should be washed before use, and the dropper tip must not touch the eye or any surface.

Serious risks, though uncommon, include severe allergic reactions, paradoxical increase in intra‑ocular pressure, corneal edema, anterior uveitis, and sudden loss of vision. Patients should seek immediate medical attention if they experience intense eye pain, vision changes, or signs of an allergic response.

Latanoprost should be avoided in patients with known hypersensitivity to Latanoprost or any component of the formulation, active ocular infections, or those who have experienced severe adverse reactions to prostaglandin analogs. A qualified eye‑care professional should evaluate suitability before initiating therapy.